A Study of Isoprinosine in Patients With Lymph Node Disease
A Study of Isoprinosine in Patients With Lymph Node Disease
The objectives of this study are to determine the effects of isoprinosine in patients
 diagnosed as having unexplained generalized lymphadenopathy. Variables to be examined will
 include:

 Signs and symptoms:

 -  Lymphadenopathy.

 -  Fever.

 -  Weight loss.

 -  Occurrence of opportunistic infections.

 Cell-mediated immune system parameters:

 -  T-helper cell (OKT4) numbers and proportions.

 -  T-suppressor cell (OKT8) numbers and proportions.

 -  Natural killer (NK) cell activity.

 -  Lymphocyte blastogenic response to phytohemagglutinin (PHA).

 -  Lymphocyte blastogenic response to pokeweed mitogen (PWM).

 -  Immunoglobulin (IgG, IgA, IgM, IgE, IgD) profile.

 -  Circulating immune complexes. Infections characteristically associated with AIDS, such
 as Candida albicans, Pneumocystis carinii pneumonia, Cytomegalovirus, Herpes simplex,
 Cryptococcus, Histoplasma, Toxoplasma, Cryptosporidium, Mycobacterium avium-
 intracellulare, Legionella, and Isospora.

 Safety parameters:

 -  Blood chemistry including serum uric acid (PurposeA-12).

 -  Complete blood count (CBC).

 -  Platelet count.
Exclusion Criteria

 Co-existing Condition:

 Patients with a history of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal
 dysfunction, or gastric ulceration are excluded.

 Concurrent Medication:

 Excluded:

 -  Systemic corticosteroids.

 -  Cytotoxic immunosuppressive agents.

 -  Radiotherapy.

 Critically ill patients or those with CDC-defined AIDS are excluded.

 Prior Medication:

 Excluded within 1 month of study entry:

 -  Immunotherapy.

 Patients with persistent generalized lymphadenopathy (PGL).